Nexalin Technology Inc
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman.
Holds 654783.0x more cash than debt — a strong balance sheet.
Current Price
$0.38
+0.03%GoodMoat Value
$0.08
79.4% overvaluedNexalin Technology Inc (NXL) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Nexalin Technology Inc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $301647.00. Gross profit (TTM) is $240274.00. EBITDA is $-8.20M. Earnings per share (EPS) is $-0.50. The P/E ratio is -0.86. Market capitalization is $7.10M.
Free cash flow (FCF) is $-4.96M. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 6 years from FY20 to FY25. Net income history spans 6 years. Free cash flow and capital expenditure data spans 6 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Nexalin Technology Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
